Sclerotherapy with low-dose 5% ethanolamine oleate in oral vascular anomalies: a retrospective study

To describe the characteristics and outcomes of a cohort of patients with oral vascular anomalies (OVA) treated with sclerotherapy using 5% ethanolamine oleate at a dosage of 0.1 mL per 10 mm of lesion size.

Sixty-seven patients were selected from a review of 300 medical records of individuals who had been diagnosed with OVA. Clinicodemographic characteristics and treatment outcomes were analyzed descriptively and analytically.

The overall mean number of sclerotherapy sessions required for clinical healing was 1.1, with lesions up to 6 mm typically requiring only one session. The mean volume of 5% ethanolamine oleate administered was 0.1 mL; however, 97.1% of lesions up to 6 mm were successfully treated with a maximum dose of 0.05 mL. Patients with papular lesions had a significantly lower rate of clinical healing compared to those with macular lesions (OR=0.79; [0.64-0.96]; p=.021). The average time to clinical healing was 16.0 days, with lesions up to 6 mm generally healing within 14 days. Complete clinical healing was achieved in 65.7% of cases.

The low-dose sclerotherapy protocol using 5% ethanolamine oleate is effective for treating OVA, particularly for lesions measuring up to 6 mm in diameter.